CXCR3 and neoplasm: The CXCR3 axis could also be indirectly targeted by the inhibition of PKA in T cells, via the expression of intracellular inhibitor regulatory subunit anchoring disruptor (RIAD)—a small peptide that inhibits the association of PKA and ezrin, resulting in increased CXCR3, increasing the tumour infiltration and treatment efficacy of CAR T cell treatment [54].